AI assistant
NEOGENOMICS INC — Director's Dealing 2018
Dec 14, 2018
32227_dirs_2018-12-14_baaab669-0586-4d2a-ae1e-004061515764.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: NEOGENOMICS INC (NEO)
CIK: 0001077183
Period of Report: 2018-12-12
Reporting Person: Weiss Lawrence Martin (Chief Scientific Officer)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $6.98 | 2021-03-01 | Common Stock (50000.0) | Direct | |
| Stock Option (Right to Buy) | $7.27 | 2022-05-25 | Common Stock (20000.0) | Direct | |
| Stock Option (Right to Buy) | $9.22 | 2023-04-19 | Common Stock (20000.0) | Direct |
Footnotes
F1: On March 1, 2016, Dr. Weiss was granted an option to purchase shares of NeoGenomics, Inc. common stock. This option vests ratably over the first three anniversary dates of the grant date.
F2: On May 25, 2017, Dr. Weiss was granted an option to purchase shares of NeoGenomics, Inc. common stock. This option vests ratably over the first three anniversary dates of the grant date.
F3: On April 19, 2018, Dr. Weiss was granted an option to purchase shares of NeoGenomics, Inc. common stock. This option vests ratably over the first three anniversary dates of the grant date.